Q2 Earnings Estimate for Liquidia Issued By Lifesci Capital

Liquidia Co. (NASDAQ:LQDA) – Equities research analysts at Lifesci Capital issued their Q2 2025 earnings estimates for shares of Liquidia in a report issued on Wednesday, March 19th. Lifesci Capital analyst C. Jubinville forecasts that the company will post earnings of ($0.35) per share for the quarter. The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share. Lifesci Capital also issued estimates for Liquidia’s Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.41) EPS.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). The company had revenue of $2.92 million during the quarter, compared to the consensus estimate of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%.

Several other research analysts have also recently issued reports on LQDA. Needham & Company LLC increased their price target on Liquidia from $19.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday. Wells Fargo & Company assumed coverage on Liquidia in a research note on Friday, December 20th. They set an “overweight” rating and a $20.00 price target for the company. Scotiabank upped their price objective on Liquidia from $30.00 to $34.00 and gave the company a “sector outperform” rating in a report on Thursday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $29.00 target price on shares of Liquidia in a report on Thursday. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Liquidia currently has a consensus rating of “Buy” and an average price target of $26.63.

Liquidia Stock Down 2.1 %

Liquidia stock opened at $15.12 on Monday. Liquidia has a 52-week low of $8.26 and a 52-week high of $16.92. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -9.28 and a beta of 0.07. The firm has a 50-day moving average price of $14.79 and a two-hundred day moving average price of $12.23.

Institutional Investors Weigh In On Liquidia

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Corebridge Financial Inc. grew its holdings in shares of Liquidia by 2.3% in the 4th quarter. Corebridge Financial Inc. now owns 31,516 shares of the company’s stock valued at $371,000 after buying an additional 694 shares during the period. Catalina Capital Group LLC grew its stake in shares of Liquidia by 6.5% during the 4th quarter. Catalina Capital Group LLC now owns 18,307 shares of the company’s stock worth $215,000 after acquiring an additional 1,125 shares in the last quarter. Cetera Investment Advisers lifted its position in shares of Liquidia by 4.3% in the fourth quarter. Cetera Investment Advisers now owns 31,243 shares of the company’s stock worth $367,000 after purchasing an additional 1,277 shares in the last quarter. Summit Investment Advisors Inc. increased its stake in Liquidia by 35.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock valued at $78,000 after buying an additional 1,719 shares during the last quarter. Finally, Sigma Planning Corp increased its position in shares of Liquidia by 3.4% in the fourth quarter. Sigma Planning Corp now owns 65,210 shares of the company’s stock valued at $767,000 after acquiring an additional 2,115 shares during the last quarter. Institutional investors own 64.54% of the company’s stock.

Insider Activity

In related news, CFO Michael Kaseta sold 23,370 shares of the company’s stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $275,298.60. Following the completion of the transaction, the chief financial officer now directly owns 401,755 shares in the company, valued at approximately $4,732,673.90. This represents a 5.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Rajeev Saggar sold 2,445 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $13.00, for a total transaction of $31,785.00. Following the sale, the insider now directly owns 267,943 shares in the company, valued at $3,483,259. This represents a 0.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 71,245 shares of company stock valued at $843,326. 30.10% of the stock is owned by company insiders.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).